References
  1. National Institute for Health and Care Excellence. Menopause: diagnosis and management; 2021. Accessed: 2021-07-11. https://www.nice.org.uk/guidance/ng23
  2. Pentti K, Honkanen R, Tuppurainen MT, Sandini L, Kroger H, Saarikoski S. Hormone replacement therapy and mortality in 52 to 70 year old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. European journal of endocrinology. 2006;154(1):101–107.
  3. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Annals of internal medicine. 2000;133(12):933– 941.
  4. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of internal medicine. 1992;117(12):1016–1037.
  5. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet. 2019 Sep 28;394(10204):1159-68.
  6. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstetrics & Gynecology. 1995;85(2):304–313.
  7. Collaborators MWS, Beral V, Bull D, Reeves G. Endometrial cancer and hormone replacement therapy in the Million Women Study. The Lancet. 2005;365:1543–51.
  8. Collaborators MWS, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. The Lancet. 2007;369(9574):1703–1710.
  9. Collaborators MWS, et al. Breast cancer and hormone replacement therapy in the Million Women Study. The Lancet. 2003;362(9382):419–27.
  10. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. New England Journal of Medicine. 2003;349(6):535–545.
  11. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort. International journal of cancer. 1996;67(3):327–332.
  12. Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer mortality. The Lancet. 2019;394(10204):1139.
  13. Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. American Journal of Obstetrics & Gynecology. 2007;196(4):342.e1– 342.e9.
  14. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. American Journal of Public Health. 1995;85(8):1128–1132.
  15. Ettinger B, Friedman GD, Bush T, Quesenberry Jr CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstetrics & Gynecology. 1996;87(1):6–12.
  16. Hunt K, Vessey M, MCPHERSON K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. BJOG: An International Journal of Obstetrics & Gynaecology. 1987;94(7):620–635.
  17. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. New England Journal of Medicine. 1997;336(25):1769–1776.
  18. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. The American journal of medicine. 2009;122(11):1016–1022.
  19. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. Jama. 2017;318(10):927–938.
  20. Benkhadra K, Mohammed K, Al Nofal A, Carranza Leon BG, Alahdab F, Faubion S, et al. Menopausal hormone therapy and mortality: a systematic review and metaanalysis. The Journal of Clinical Endocrinology & Metabolism. 2015;100(11):4021– 4028.
  21. Holm M, Olsen A, Au Yeung S, Overvad K, Lidegaard Ø, Kroman N, et al. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG: An International Journal of Obstetrics & Gynaecology. 2019;126(1):55–63.
  22. Malek AM, Vladutiu CJ, Meyer ML, Cushman M, Newman R, Lisabeth LD, et al. The association of age at menopause and all-cause and cause-specific mortality by race, postmenopausal hormone use, and smoking status. Preventive medicine reports. 2019;15:100955.
  23. Stram DO, Liu YO, Henderson KD, Sullivan-Halley J, Luo J, Saxena T, et al. Agespecific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause (New York, NY). 2011;18(3):253.
  24. British Medical Association. Verification of death (VoD); 2020. Accessed: 2021-09-10. https://www.bma.org.uk/media/2843/ bma-verification-of-death-vod-july-2020.pdf.
  25. Blak B, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Journal of Innovation in Health Informatics. 2011;19(4):251–255.
  26. IQVIA Medical Research Data. Data collection arrangements; 2017. Accessed: 2020-07-28. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/the-health-improvement-network-thin-database/.
  27. Bradley SH, Lawrence NR, Carder P. Using primary care data for health research in England–an overview. Future healthcare journal. 2018;5(3):207.
  28. The Health Foundation. Female sex hormones and their modulators; 2018. Accessed: 2018-09-10. https://openprescribing.net/bnf/060401/.
  29. Big Health Actuarial Data Project. http://www.bighealthactuarialdata.ac.uk/team.
  30. Springate DA, Kontopantelis E, Ashcroft DM, Olier I, Parisi R, Chamapiwa E, et al. ClinicalCodes: an online clinical codes repository to improve the validity and reproducibility of research using electronic medical records. PloS one. 2014;9(6):e99825.
  31. Norman P, Darlington-Pollock F. The changing geography of deprivation in Great Britain: exploiting small area census data, 1971 to 2011. In: The Routledge Handbook of Census Resources, Methods and Applications. Routledge; 2017. p. 404–420.
  32. Peng M, Chen G, Kaplan GG, Lix LM, Drummond N, Lucyk K, et al. Methods of defining hypertension in electronic medical records: validation against national survey data. Journal of Public Health. 2016;38(3):e392–e399.
  33. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26.
  34. Begun A, Kulinskaya E, MacGregor AJ. Risk-adjusted CUSUM control charts for shared frailty survival models with application to hip replacement outcomes: a study using the NJR dataset. BMC medical research methodology. 2019;19(1):1–15.
  35. Marshall A, Altman DG, Holder RL. Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: a resampling study. BMC medical research methodology. 2010;10(1):1–10.
  36. Van Buuren S. Flexible imputation of missing data. CRC press; 2018.
  37. Rubin DB. Multiple imputation for survey nonresponse. New York: Wiley; 1987.
  38. Therneau T, Atkinson E. The concordance statistic. 2020.
  39. Gillam SJ, Siriwardena AN, Steel N. Pay-for-performance in the United Kingdom: impact of the quality and outcomes framework—a systematic review. The Annals of Family Medicine. 2012;10(5):461–468.
  40. Bromley S, Vries C, Farmer R. Utilisation of hormone replacement therapy in the United Kingdom. BJOG: An International Journal of Obstetrics & Gynaecology. 2004;111(4):369–76.
  41. Kontopantelis E, Stevens RJ, Helms PJ, Edwards. Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population study. BMJ open. 2018;8(2):e020738.
  42. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women. Journal of general internal medicine. 2004;19(7):791–804.
  43. Drever F, Whitehead M. Mortality in regions and local authority districts in the 1990s: exploring the relationship with deprivation. Population trends. 1995;(82):19– 26.
  44. NICE. Menopause: diagnosis and management; 2019. Accessed: 2021-09-23. https://www.nice.org.uk/guidance/ng23/chapter/Recommendations#long-term-benefits-and-risks-of-hormone-replacement-therapy.